EWSR1 and metastatic neoplasm: Although important insights into EWS pathogenesis have emerged in recent years, EWS patient treatment is still confined to dense multidrug chemotherapy, and the prognosis of high-risk patients remains dismal, with a less than 40% of survival rate at 5 years for patients with metastatic disease at diagnosis and for those who relapse after first-line treatment (1–3).